Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cholestyramine for Reducing PFAS Body Burden
NCT07836023Phase 2Not yet recruiting
- Sponsor
- Emory University
- Start
- Nov 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cholestyramine in environmental exposure, sponsored by Emory University. Primary endpoint: Serum NASEM ΣPFAS concentration at Day 120. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
cholestyramine
03
Conditions
environmental exposure
Beyond the preview
Go deeper on NCT07836023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07836023.